De novo design of potent inhibitors of clostridial family toxins

R Robert J. Ragotte H Huazhu Liang (Molecular Medicine Program, The Hospital for Sick Children) J John Tam S Sean Miletic (Molecular Medicine Program, The Hospital for Sick Children) J Jacob M. Berman R Roger Palou (Molecular Medicine Program, The Hospital for Sick Children) C Connor Weidle Z Zhijie Li (Molecular Medicine Program, The Hospital for Sick Children) M Matthias Glögl (Department of Biochemistry, University of Washington) G Greg L. Beilhartz (Molecular Medicine Program, The Hospital for Sick Children) K Kenneth D. Carr A Andrew J. Borst B Brian Coventry X Xinru Wang J John L. Rubinstein (Molecular Medicine Program, The Hospital for Sick Children) M Mike Tyers (Molecular Medicine Program, The Hospital for Sick Children) D Daniel Schramek R Roman A. Melnyk D David Baker

Abstract

Clostridioides difficile remains a leading cause of hospital-acquired infections, with its primary virulence factor, toxin B (TcdB), responsible for severe colitis and recurrent disease. The closely related toxin, TcsL, from Paeniclostridium sordellii , causes a rarer but often fatal toxic shock syndrome, particularly in gynecological and obstetric contexts. We report the de novo design of small protein minibinders that directly neutralize TcdB and TcsL by preventing their entry into host cells. Using deep learning and Rosetta-based approaches, we generated high-affinity minibinders that protect cells from intoxication with picomolar potency and, in the case of TcsL, prolonged survival following lethal toxin challenge in mice. The designed proteins against TcdB demonstrate exceptional stability in proteolytic and acidic environments, making them well-suited for oral delivery—a valuable feature for treating C. difficile infections localized to the gastrointestinal tract. For TcsL, potent inhibitors were identified from 48 initial designs and 48 optimized designs, highlighting the potential of computational design for rapidly developing countermeasures against life-threatening bacterial toxins.

Article Details

Volume / Issue Vol. 122, Issue 39
Published September 30, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (19)

R

Robert J. Ragotte

H

Huazhu Liang

Molecular Medicine Program, The Hospital for Sick Children

J

John Tam

S

Sean Miletic

Molecular Medicine Program, The Hospital for Sick Children

J

Jacob M. Berman

R

Roger Palou

Molecular Medicine Program, The Hospital for Sick Children

C

Connor Weidle

Z

Zhijie Li

Molecular Medicine Program, The Hospital for Sick Children

M

Matthias Glögl

Department of Biochemistry, University of Washington

G

Greg L. Beilhartz

Molecular Medicine Program, The Hospital for Sick Children

K

Kenneth D. Carr

A

Andrew J. Borst

B

Brian Coventry

X

Xinru Wang

J

John L. Rubinstein

Molecular Medicine Program, The Hospital for Sick Children

M

Mike Tyers

Molecular Medicine Program, The Hospital for Sick Children

D

Daniel Schramek

R

Roman A. Melnyk

D

David Baker